In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
After finishing at $4.43 in the prior trading day, Terns Pharmaceuticals Inc (NASDAQ: TERN) closed at $4.45, up 0.45%. In other words, the price has increased by $0.45 from its previous closing price. On the day, 2.09 million shares were traded. TERN stock price reached its highest trading level at $4.66 during the session, while it also had its lowest trading level at $4.41.
Ratios:
Our goal is to gain a better understanding of TERN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 32.99 and its Current Ratio is at 32.99. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on October 31, 2024, initiated with a Outperform rating and assigned the stock a target price of $82.
On June 22, 2023, Mizuho started tracking the stock assigning a Buy rating and target price of $16.
On June 07, 2023, Jefferies started tracking the stock assigning a Buy rating and target price of $18.Jefferies initiated its Buy rating on June 07, 2023, with a $18 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 02 ’25 when Kuriakose Emil sold 4,481 shares for $5.71 per share. The transaction valued at 25,607 led to the insider holds 54,269 shares of the business.
Vignola Mark J. sold 9,059 shares of TERN for $52,500 on Jan 06 ’25. The Chief Financial Officer now owns 74,752 shares after completing the transaction at $5.80 per share. On Jan 02 ’25, another insider, Vignola Mark J., who serves as the Chief Financial Officer of the company, sold 8,129 shares for $5.72 each. As a result, the insider received 46,524 and left with 83,811 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TERN now has a Market Capitalization of 377978080 and an Enterprise Value of 6408539.
Stock Price History:
The Beta on a monthly basis for TERN is -0.34, which has changed by -0.17962962 over the last 52 weeks, in comparison to a change of 0.23171377 over the same period for the S&P500. Over the past 52 weeks, TERN has reached a high of $11.40, while it has fallen to a 52-week low of $4.32. The 50-Day Moving Average of the stock is -26.10%, while the 200-Day Moving Average is calculated to be -35.61%.
Shares Statistics:
The stock has traded on average 1.65M shares per day over the past 3-months and 1599020 shares per day over the last 10 days, according to various share statistics. A total of 84.92M shares are outstanding, with a floating share count of 62.32M. Insiders hold about 26.63% of the company’s shares, while institutions hold 71.53% stake in the company. Shares short for TERN as of 1735603200 were 7369540 with a Short Ratio of 4.45, compared to 1732838400 on 5385026. Therefore, it implies a Short% of Shares Outstanding of 7369540 and a Short% of Float of 9.54.
Earnings Estimates
The current rating of Terns Pharmaceuticals Inc (TERN) is the result of assessments by 9.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.27 and low estimates of -$0.38.
Analysts are recommending an EPS of between -$1.13 and -$1.24 for the fiscal current year, implying an average EPS of -$1.19. EPS for the following year is -$1.32, with 9.0 analysts recommending between -$1.13 and -$1.48.
